Cite

HARVARD Citation

    Hecht, J. et al. (n.d.). A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors. Journal for immunotherapy of cancer. p. . [Online]. 
  
Back to record